Which marker is a better guide for stopping hepatitis B treatment: intrahepatic covalently closed circular DNA (cccDNA) or serum hepatitis B virus DNA (HBV‑DNA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HBV DNA is the Better Guide to Stop Hepatitis B Treatment

Serum HBV DNA is the practical and guideline-recommended marker for stopping hepatitis B treatment, while cccDNA, though theoretically superior, is not clinically accessible and therefore cannot guide treatment decisions. 1

Why HBV DNA is Used in Clinical Practice

The 2025 EASL guidelines explicitly base treatment discontinuation decisions on serum HBV DNA levels combined with other markers, not cccDNA 1. The algorithm for stopping nucleos(t)ide analogue (NA) therapy requires:

For HBeAg-Positive Patients:

  • HBeAg/anti-HBe seroconversion
  • Undetectable HBV DNA
  • No advanced liver disease
  • Low HBsAg level (<300 IU/ml for Asians, <1,000 IU/ml for Caucasians)
  • At least 12 months consolidation therapy after seroconversion 1

For HBeAg-Negative Patients:

  • Undetectable HBV DNA
  • No advanced liver disease
  • Low HBsAg level
  • At least 12 months consolidation therapy 1

After stopping treatment, HBV DNA monitoring is mandatory at least monthly for 6 months, then every 3 months for 12-24 months. Re-treatment should be considered when HBV DNA exceeds 10,000 IU/ml and initiated no later than HBV DNA ≥100,000 IU/ml 1.

The cccDNA Problem: Superior in Theory, Impractical in Reality

While cccDNA is the true molecular reservoir of HBV persistence and theoretically the ideal marker 2, 3, it has critical limitations:

cccDNA requires liver biopsy for measurement - it cannot be reliably measured in serum and requires invasive tissue sampling 2, 4. This makes it completely impractical for routine monitoring of treatment discontinuation, which requires serial measurements over months to years.

Research shows that at end of treatment, intrahepatic cccDNA levels predict sustained virologic response better than serum HBV DNA 2. However, this advantage disappears during long-term NA therapy - at 96 weeks of treatment, cccDNA no longer correlates well with serum markers except HBsAg 4.

Serum Markers as cccDNA Surrogates

Before treatment, serum HBV DNA correlates moderately with intrahepatic cccDNA (r=0.64-0.92) 4, 5, 6. The combination of HBV DNA plus HBV RNA shows the strongest correlation with cccDNA (r=0.698) 5.

During and after NA treatment, these correlations weaken significantly 4. At 96 weeks of NA therapy, only HBsAg decline correlates with cccDNA decline (r=0.39), while HBV DNA and HBV RNA lose their predictive value 4.

Critical Caveat About HBsAg

A major 2026 study reveals that HBsAg cannot distinguish between cccDNA activity and integrated HBV DNA expression 7. Integrated HBV DNA can produce HBsAg indistinguishable from cccDNA-derived HBsAg in composition, secretion, and tissue distribution. This means HBsAg loss may not truly reflect cccDNA elimination, challenging its use as a functional cure endpoint 7.

Practical Clinical Algorithm

Use serum HBV DNA as your primary stopping criterion because:

  1. It's non-invasive and readily available
  2. It's what current guidelines mandate for monitoring 1
  3. cccDNA measurement requires liver biopsy, making serial monitoring impossible
  4. HBV DNA suppression to undetectable levels, combined with appropriate consolidation therapy duration, provides acceptable relapse prediction

Enhance decision-making by adding:

  • HBsAg quantification (lower levels predict better sustained response)
  • HBeAg status (for HBeAg-positive patients)
  • Liver disease stage (never stop in decompensated cirrhosis)
  • Close post-treatment monitoring with HBV DNA and ALT 1

The reality is that cccDNA, while the gold standard for understanding HBV persistence, has no role in routine clinical decision-making for treatment discontinuation because it cannot be practically measured. Guidelines universally rely on serum HBV DNA for this reason 1.

References

6
Research

[Intrahepatic hepatitis B virus covalently closed circular DNA correlation with serum HBV DNA, serum HBsAg, alanine aminotransferase and age].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015

Related Questions

When is blood glucose considered controlled in gestational diabetes mellitus, and what percentage elevation above normal fasting glucose is acceptable?
What is the recommended adult dose of pyrantel pamoate for treatment?
In a 36‑month‑old child with suspected helminth infection presenting with itching and pain, should pyrantel pamoate be used, what is the appropriate dose for the child and for all household members, and can the adult be treated with mebendazole?
What are the surgical guidelines for managing high‑grade endometrial carcinoma?
Among benzodiazepines, benztropine, sertraline, and risperidone, which medication is most likely to cause hair loss?
What medication is recommended to control palpitations in a patient with hyperthyroidism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.